Rabbit polyclonal antibody raised against synthetic peptide of AKT1.
A synthetic peptide (conjugated with KLH) corresponding to N-terminus of human AKT1.
Protein A purification
ELISA (1:1000) Western Blot (1:50-100) Immunohistochemistry (1:50-100) The optimal working dilution should be determined by the end user.
In PBS (0.09% sodium azide)
Store at 4°C. For long term storage store at -20°C. Aliquot to avoid repeated freezing and thawing.
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Western Blot (Transfected lysate)
Western blot analysis of AKT1 polyclonal antibody (Cat # PAB2694) (arrow). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the AKT1 gene (Lane 2) (Origene Technologies).
Formalin-fixed and paraffin-embedded human breast carcinoma reacted with AKT1 polyclonal antibody (Cat # PAB2694) , which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry ; clinical relevance has not been evaluated.
The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq